Wedbush began coverage on shares of Gossamer Bio (NASDAQ:GOSS – Get Rating) in a research note released on Monday, Marketbeat reports. The firm issued an outperform rating and a $24.00 price objective on the stock.

A number of other brokerages have also recently commented on GOSS. HC Wainwright reiterated a buy rating and issued a $20.00 target price on shares of Gossamer Bio in a report on Thursday, July 14th. Raymond James lifted their target price on Gossamer Bio from $10.00 to $14.00 and gave the stock an outperform rating in a report on Thursday, July 14th. Finally, Barclays lifted their target price on Gossamer Bio from $12.00 to $18.00 and gave the stock an overweight rating in a report on Wednesday, August 17th. Ten investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company has a consensus rating of Buy and a consensus price target of $19.33.

Gossamer Bio Stock Performance

NASDAQ GOSS opened at $13.52 on Monday. The stock has a market capitalization of $1.27 billion, a PE ratio of -4.45 and a beta of 0.92. The business has a 50 day simple moving average of $12.99 and a two-hundred day simple moving average of $9.79. The company has a debt-to-equity ratio of 7.44, a current ratio of 5.24 and a quick ratio of 5.24. Gossamer Bio has a 1-year low of $5.64 and a 1-year high of $15.19.

Insider Activity at Gossamer Bio

In other Gossamer Bio news, insider Laura Carter acquired 6,934 shares of the company's stock in a transaction that occurred on Friday, July 15th. The stock was bought at an average price of $7.21 per share, for a total transaction of $49,994.14. Following the acquisition, the insider now directly owns 87,168 shares in the company, valued at $628,481.28. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In other news, CEO Faheem Hasnain bought 138,696 shares of the firm's stock in a transaction on Friday, July 15th. The stock was acquired at an average cost of $7.21 per share, with a total value of $999,998.16. Following the transaction, the chief executive officer now directly owns 3,617,325 shares in the company, valued at approximately $26,080,913.25. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Laura Carter bought 6,934 shares of the firm's stock in a transaction on Friday, July 15th. The shares were purchased at an average cost of $7.21 per share, with a total value of $49,994.14. Following the completion of the transaction, the insider now owns 87,168 shares in the company, valued at $628,481.28. The disclosure for this purchase can be found here. Insiders acquired a total of 159,499 shares of company stock worth $1,149,988 in the last quarter. 8.30% of the stock is owned by company insiders.

Institutional Investors Weigh In On Gossamer Bio

A number of institutional investors and hedge funds have recently bought and sold shares of GOSS. Millennium Management LLC raised its position in Gossamer Bio by 281.0% during the 2nd quarter. Millennium Management LLC now owns 1,480,705 shares of the company's stock valued at $12,394,000 after purchasing an additional 1,092,018 shares in the last quarter. Woodline Partners LP bought a new stake in Gossamer Bio during the 4th quarter valued at $11,059,000. Point72 Asset Management L.P. bought a new stake in Gossamer Bio during the 2nd quarter valued at $8,064,000. Kynam Capital Management LP raised its position in Gossamer Bio by 80.2% during the 1st quarter. Kynam Capital Management LP now owns 1,832,704 shares of the company's stock valued at $15,908,000 after purchasing an additional 815,847 shares in the last quarter. Finally, State Street Corp raised its position in Gossamer Bio by 17.1% during the 2nd quarter. State Street Corp now owns 3,875,194 shares of the company's stock valued at $32,435,000 after purchasing an additional 567,264 shares in the last quarter. 67.57% of the stock is owned by institutional investors.

Gossamer Bio Company Profile

(Get Rating)

Gossamer Bio, Inc, a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colonystimulating factor 1 receptor, or CSF1R, and c-KIT inhibitor for the treatment of pulmonary arterial hypertension; GB004, a gut-targeted, oral small molecule for the treatment of inflammatory bowel disease; GB5121, an oral, irreversible, covalent, small molecule inhibitor of Bruton's Tyrosine Kinase for the treatment of primary central nervous system lymphoma; and GB7208, an oral, small molecule, BTK inhibitor for the treatment of multiple sclerosis.

Featured Articles

• Get a free copy of the StockNews.com research report on Gossamer Bio (GOSS)
• Oracle's Short-Term Pain Could Be Your Long-Term Gain
• Lucid is Looking Like a Clear EV Winner
• Still Lovin' It: Investors Keep Visiting McDonald's
• Did FedEx Just Deliver A Buying Opportunity?
• Autozone Shifts Back Into Rally-Mode, New Highs Are In Sight

Receive News & Ratings for Gossamer Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gossamer Bio and related companies with MarketBeat.com's FREE daily email newsletter.